<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The treatment course of <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0001907'>thromboembolic events</z:hpo> in the patients with congenital deficiency of antithrombin III (AT III) in the national Swedish register was reviewed in order to assess the appropriate medical therapy in this situation </plain></SENT>
<SENT sid="1" pm="."><plain>The medical treatment of 70 events of venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> was evaluated </plain></SENT>
<SENT sid="2" pm="."><plain>There were eight cases with signs of clinical progression </plain></SENT>
<SENT sid="3" pm="."><plain>The risk of therapeutic failure with <z:chebi fb="5" ids="28304">heparin</z:chebi> could be as low as 1.5% or as high as 9.2% </plain></SENT>
<SENT sid="4" pm="."><plain>It would not be cost-effective to substitute with concentrates of AT III in every case with congenital deficiency thereof in connection with <z:hpo ids='HP_0011009'>acute</z:hpo> venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo>. "<z:chebi fb="5" ids="28304">Heparin</z:chebi> resistance" does not seem to be a problem in the vast majority of these patients </plain></SENT>
</text></document>